UISS ONCO
UISS-MC
Mammary Carcinoma. Non-animal alternative to test new vaccines to prevent mammary carcinoma.
UISS-TC
Thyroid Carcinoma.This computational framework has been designed to suggest new potential targets to overcome drug resistance.
UISS-MELANOMA
The biologically oriented in silico model has been used to predict treatment failure or success in pre-clinical conditions eventually leading new promising in vivo experiments.
UISS AUTO-IMMUNE
UISS-MS
Multiple Sclerosis. The most advanced product in the catalogue. The Simulator is able to reproduce different immune repertoires for an identified patient.
UISS RE-VAX
UISS-COVID19
In silico trials are showing to be powerful weapons in predicting immune responses of potential candidate vaccines. Here, UISS has been extended to be used as an in silico trial platform to speed-up and drive the discovery pipeline of vaccine against SARS-CoV-2.
UISS-FLU
In silico simulations suggested a good immune efficacy of specific citrus-derived adjuvant (Beta Sitosterol) that was then confirmed in vivo .
Threathment
We also offer different types of packages:
- Mimesis Evolution: Integrating a disease model and a drug that does not belong to the same class as the ones already featured in the catalogue
- Mimesis Custom: Conducting an entirely new study on a disease not present in the catalogue
- Pathophysiological models not based on UISS can be developed upon request